Lexaria Bioscience (LEXX) Other Non-Current Liabilities (2012 - 2021)
Lexaria Bioscience's (LEXX) quarterly Other Non-Current Liabilities came in at $49989.0 in Q3 2021, down 44.08% year-on-year from $89393.0 in Q3 2020, and down 44.08% quarter-over-quarter from $89393.0 in Q3 2020.
Lexaria Bioscience (LEXX) Other Non-Current Liabilities (2012 - 2021) Analysis & Trends
Lexaria Bioscience has disclosed Other Non-Current Liabilities across 5 years of filings, most recently posting $49989.0 for Q3 2021.
- Other Non-Current Liabilities for Q3 2021 came in at $49989.0, down 44.08% year-over-year; the trailing twelve-month figure through Aug 2021 was $49989.0 (down 44.08% YoY), and the FY2021 annual result was $49989.0, down 44.08% from the prior year.
- Other Non-Current Liabilities came in at $49989.0 for Q3 2021 at Lexaria Bioscience, down from $89393.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $89393.0 in Q3 2020 to a low of $49989.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2021 | 49,989.00 |
| Aug 31, 2020 | 89,393.00 |
| Jul 31, 2014 | 59,245.00 |
| Apr 30, 2014 | 59,245.00 |
| Jan 31, 2014 | 59,245.00 |
| Oct 31, 2013 | 59,245.00 |
| Jul 31, 2013 | 59,245.00 |
| Apr 30, 2013 | 59,245.00 |
| Jan 31, 2013 | 59,245.00 |
| Oct 31, 2012 | 59,245.00 |